From: Detection methods predict differences in biology and survival in breast cancer patients
Prevalent (n = 76) vs. Incident screened (n = 65) | P value | OR | |
---|---|---|---|
Mean age | 56.88 ± 0.65 vs. 59.71 ± 0.68 | P < 0.01 | 0.91 (0.86-0.98) |
Mean size (cm) | 1.64 ± 0.15 vs. 1.27 ± 0.17 | p < 0.05 | 1.44 (1.01-2.08) |
Lymph node positive | 25% vs. 21.5% | N.S. | 1.21 (0.55-2.66) |
Poorly-differentiated tumors | 32.1% vs. 32.8% | N.S. | 0.96 (0.49-1.90) |
ER positive | 87.5% vs. 89.1% | N.S. | 0.85 (0.27-2.64) |
PR positive | 70.3% vs. 78.2% | N.S. | 0.66 (0.28-1.52) |
in situ carcinomas | 13% vs. 11% | N.S. | 1.25 (0.44-3.51) |
Apoptosis | 42.5% vs. 66.7% | N.S. | 0.37 (0.12-1.11) |
Bcl-2 | 75.4% vs. 81.3% | N.S. | 0.70 (0.28-1.77) |
Ki67 | 38.5% vs. 63% | p < 0.01 | 0.36 (0.17-0.77) |
c-erb-B2 | 7.4% vs. 23% | p < 0.01 | 0.22 (0.08-0.61) |
Delay Diagnosis- treatment (>30 days) | 64.5 vs. 35.4 | p < 0.01 | 3.31 (1.65-6.62) |